Trust Signals
Key Takeaways
- Semaglutide (a GLP-1 receptor agonist peptide) produced mean body weight loss of approximately 14.9 percent in the STEP 1 RCT (n=1,961), the largest effect size of any peptide compound in human trials.
- Tesamorelin is the only GHRH-class peptide with FDA approval for fat reduction, narrowly indicated for HIV-associated visceral lipodystrophy, not general obesity.
- CJC-1295 plus Ipamorelin raises GH and IGF-1 in humans based on pharmacokinetic studies, but no published RCT has measured body composition as a primary endpoint for this combination.
- AOD-9604 advanced to human trials but failed to demonstrate sufficient efficacy for FDA approval; current evidence for fat loss in healthy adults is rated Low.
- Independent third-party assays have repeatedly found research peptides sold online to deviate from labeled purity or sequence, making Certificate of Analysis review non-optional for safety.
What Is the Best Fat Burning Peptide Stack?
The best fat burning peptide stack depends on whether you require FDA-approved evidence or are evaluating research compounds. For proven fat loss, semaglutide alone outperforms every stack combination on human trial data. For the most-used research peptide combination, CJC-1295 with Ipamorelin is the clinical standard, backed by mechanism data but not by body-composition RCTs. Understand what each tier means before choosing.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Every Major Claim Graded
- Mechanism With Numbers: How These Peptides Target Fat
- The Ranked Stacks: What the Evidence Actually Supports
- What Most Pages Get Wrong About Peptide Fat Loss
- The Chemistry Behind the Rules: Why Storage and Timing Matter
- Honest Head-to-Head: Peptide Stacks vs. Approved Alternatives
- Operational and Label Literacy: Reading COAs and Dosing Tables
- Safety, Side Effects, and Who Should Not Stack
- FAQ
- Sources
What Does the Evidence Actually Say for Each Compound?
| Compound | Best Evidence Type | Effect Direction | Population Studied | Confidence (Fat Loss) |
|---|---|---|---|---|
| Semaglutide (GLP-1 RA) | Multiple Phase 3 RCTs (STEP program) | Strong fat and weight reduction | Adults with overweight/obesity, general population | High |
| Tesamorelin (GHRH analog) | Phase 3 RCTs | Visceral fat reduction 15-20% vs. placebo | HIV-associated lipodystrophy | Moderate (narrow indication) |
| CJC-1295 (without DAC) + Ipamorelin | PK/PD human studies; GH physiology extrapolation | GH and IGF-1 elevation confirmed; fat loss unconfirmed | Healthy adults (PK only) | Low |
| AOD-9604 (GH fragment 176-191) | Early-phase human trials (industry-sponsored) | Modest signal; failed Phase 3 | Overweight adults | Low |
| BPC-157 | Animal models only | No direct fat-loss mechanism; indirect metabolic effects in rodents | Rodents | Very Low |
| MOTS-c (mitochondrial peptide) | Animal models; small human exploratory data | Improved insulin sensitivity; weight effects modest | Rodents, small human pilots | Very Low |
How Do These Peptides Target Fat? Mechanism With Specific Numbers
GH-Axis Peptides: CJC-1295 and Ipamorelin
CJC-1295 is a GHRH analog. GHRH binds the GHRH receptor (GHRHR) on pituitary somatotrophs, activating adenylyl cyclase and increasing cAMP, which drives GH synthesis and pulsatile release. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses with minimal cortisol or prolactin co-stimulation compared to older GHRPs like GHRP-6.
In a published pharmacokinetic study by Jetté and colleagues, CJC-1295 (without the Drug Affinity Complex modification) produced detectable GH elevation for roughly 1 to 2 hours post-injection, consistent with natural pulsatility. Elevated GH activates hormone-sensitive lipase in adipocytes, increasing free fatty acid release from triglyceride stores. GH also reduces lipoprotein lipase activity, limiting fat re-uptake into adipose tissue.
What this mechanism does NOT prove: stimulating lipolysis in isolation does not guarantee net fat loss. If caloric intake is not controlled, released free fatty acids are re-esterified or used for energy and replaced. Animal GH deficiency models showing dramatic fat loss do not translate directly to euthyroid, GH-sufficient adults.
Tesamorelin
Tesamorelin is a stabilized GHRH(1-44) analog with a trans-3-hexenoic acid modification that protects it from dipeptidyl peptidase IV (DPP-IV) cleavage, extending its half-life to approximately 26 minutes versus roughly 7 minutes for native GHRH. In the pivotal Falutz et al. trials, 26 weeks of daily subcutaneous injection at 2 mg reduced visceral adipose tissue by approximately 15 to 20 percent versus placebo in HIV-lipodystrophy patients. This is the strongest controlled fat-reduction data for any GHRH-class compound in humans.
AOD-9604
AOD-9604 is residues 176 to 191 of the human GH sequence, the region believed to mediate lipolytic activity without the insulin-desensitizing effects of full-length GH. In vitro and rodent data showed stimulation of lipolysis and inhibition of lipogenesis. Early human trials by Metabolic Pharmaceuticals showed some signal at oral doses, but the compound did not achieve the primary endpoint in larger trials. The FDA did not approve it for obesity. It was later classified as Generally Recognized as Safe (GRAS) as a food ingredient at much lower doses, which is a separate and lower bar.
GLP-1 Receptor Agonists: Semaglutide
Semaglutide is a GLP-1 receptor agonist peptide with 94 percent homology to native GLP-1. It reduces appetite via hypothalamic GLP-1 receptors, slows gastric emptying, and improves insulin sensitivity. The STEP 1 trial (Wilding et al., NEJM 2021, n=1,961) showed 14.9 percent mean body weight reduction at 68 weeks with 2.4 mg weekly versus 2.4 percent with placebo. This is the benchmark against which all other peptide fat-loss claims should be measured.
Which Fat Burning Peptide Stacks Are Worth Considering?
Tier 1: Approved Peptide With Human RCT Data
Semaglutide 2.4 mg weekly (Wegovy). Not a "stack," but a single peptide with the most robust fat-loss evidence available. If the goal is fat reduction with physician oversight, this is the strongest option before any research peptide is considered.
Tier 2: Research Stack With Mechanism Support (Low Confidence)
CJC-1295 (without DAC) 200-300 mcg + Ipamorelin 200-300 mcg, subcutaneous, once daily at bedtime. The rationale for bedtime dosing is real: endogenous GH is primarily secreted during slow-wave sleep, and aligning exogenous GHRH/GHRP stimulation with this window is physiologically coherent. The combination is more selective (less cortisol/prolactin stimulation) than older stacks using GHRP-2 or GHRP-6. However, fat-loss efficacy in healthy adults has not been confirmed in an RCT.
Tier 3: Add-On Compounds With Very Low Confidence
AOD-9604 is sometimes added to GHRH/GHRP stacks at 250 to 500 mcg daily. The theoretical rationale is additive lipolytic signaling, but there is no published human trial measuring this combination. MOTS-c and BPC-157 appear in online stack protocols with essentially no human fat-loss data; their inclusion is speculative.
What Most Pages Get Wrong About Fat Burning Peptide Stacks
Second omission: almost every peptide blog presents GH elevation as equivalent to fat loss. It is not. GH pulsatility promotes lipolysis acutely, but sustained supraphysiologic GH also causes insulin resistance, which can promote fat storage over time. The dose and duration at which GHRH/GHRP combinations tip from beneficial to counterproductive in metabolically healthy adults is genuinely unknown.
Third omission: the reversal problem. Tesamorelin's visceral fat reduction largely reverses within 12 weeks of stopping treatment, as shown in the Falutz extension studies. There is no published long-term maintenance data for GHRH/GHRP combinations either.
Why Do Peptides Degrade and Why Does Timing Matter?
Peptide bonds are hydrolyzed by water (hydrolysis) and attacked by oxygen (oxidation), both reactions accelerated by heat and light. Lyophilization (freeze-drying) removes water and essentially halts both reactions, which is why dry peptide powder is stable for months to years at cold temperatures.
Once you reconstitute a peptide in bacteriostatic water (0.9% benzyl alcohol), you have reintroduced water and the clock restarts. At 4 degrees Celsius (standard refrigerator temperature), most short-sequence peptides lose meaningful potency over weeks rather than days, but the exact kinetics vary by sequence, pH, and whether antioxidants are present. Methionine-containing peptides (methionine is in several GHRH analogs) are particularly vulnerable to oxidation, forming methionine sulfoxide, which reduces receptor binding affinity.
This is why "store cold, use within 28 days after reconstitution" is the standard compounding pharmacy guideline and not just caution. It is also why injecting from a vial left at room temperature for two weeks is not the same experiment as injecting a freshly reconstituted dose.
Freeze-thaw cycling is separately damaging: ice crystal formation denatures tertiary structure and causes peptide aggregation. If you must freeze reconstituted peptide, divide it into single-use aliquots first.
Honest Head-to-Head: Best Fat Burning Peptide Stack vs. Alternatives
| Approach | Best Evidence | Effect Size (Fat/Weight) | Regulatory Status | Cost Context | Where Peptide Stack Loses |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg/wk | Multiple Phase 3 RCTs | ~15% body weight loss (STEP 1) | FDA-approved (Wegovy) | High list price; insured access variable | Peptide stack wins here: cost if uninsured |
| CJC-1295 + Ipamorelin stack | Mechanism + PK studies | Unknown; no RCT data | Research compound / compounded Rx in some clinics | Moderate (compounding adds cost) | Loses on evidence, regulatory certainty, and effect-size confirmation |
| Tesamorelin alone | Phase 3 RCTs | 15-20% visceral fat reduction (specific population) | FDA-approved (Egrifta, narrow indication) | High; off-label use not covered | Loses on indication breadth and reversal after stopping |
| Tirzepatide (GIP/GLP-1 dual agonist) | Phase 3 RCTs (SURMOUNT program) | ~20-22% body weight loss (SURMOUNT-1) | FDA-approved (Zepbound for obesity) | High list price | Peptide stack loses on every efficacy metric |
| Caloric deficit plus resistance training | Extensive RCT base | 5-10% body weight loss; superior lean mass preservation | No regulatory needed | Low to moderate | Peptide stacks are almost always studied atop this; they are not a replacement for it |
How to Read a COA and Dose a Peptide Stack Correctly
Certificate of Analysis: What to Demand
A legitimate COA for a research peptide should include: identity confirmation by high-performance liquid chromatography (HPLC) and mass spectrometry (MS), purity expressed as area percent (accept nothing below 98% for injectables), endotoxin testing result in EU/mL (less than 1 EU/mL per mL is the injectable standard), and the date of testing. If the COA comes from the same company selling you the peptide without naming an independent third-party lab, it is not independently verified.
Reconstitution Math
Standard approach: if you have a 5 mg vial of Ipamorelin and want 250 mcg doses, add 2 mL of bacteriostatic water. This gives you a concentration of 2.5 mg per mL, or 2,500 mcg per mL. A 250 mcg dose then requires 0.1 mL (10 units on a 100-unit insulin syringe). Write the concentration on the vial. Dosing errors almost always come from skipping this step.
| Vial Size | Bacteriostatic Water Added | Resulting Concentration | Volume per 200 mcg Dose |
|---|---|---|---|
| 2 mg | 1 mL | 2,000 mcg/mL | 0.10 mL (10 units) |
| 5 mg | 2 mL | 2,500 mcg/mL | 0.08 mL (8 units) |
| 5 mg | 5 mL | 1,000 mcg/mL | 0.20 mL (20 units) |
| 10 mg | 2 mL | 5,000 mcg/mL | 0.04 mL (4 units) |
What a Degraded Peptide Looks Like
Lyophilized powder should be white to off-white and adhere loosely to the vial. Yellow or amber powder before reconstitution suggests oxidation. After reconstitution, the solution should be clear and colorless; cloudiness or visible flakes suggest aggregation or contamination. A vial with a broken or compromised rubber stopper seal is a contamination risk regardless of visual appearance.
Who Should Not Use a Fat Burning Peptide Stack?
GH-stimulating peptides are contraindicated or require caution in: active malignancy (GH/IGF-1 promotes cell proliferation), diabetic or pre-diabetic states (GH causes insulin resistance), individuals with pituitary disease, and those under 18 or over 65 without physician involvement. Pregnancy and breastfeeding are absolute contraindications for all compounds discussed here.
GLP-1 receptor agonists including semaglutide carry a boxed warning for thyroid C-cell tumors (observed in rodents; relevance in humans uncertain) and are contraindicated in personal or family history of medullary thyroid carcinoma or MEN type 2.
Water retention, carpal tunnel symptoms, and transient glucose elevation are the most commonly reported side effects of GH-stimulating compounds in clinical use. These are dose-dependent and generally resolve with dose reduction.
There are no published human pharmacokinetic or safety studies on GHRH/GHRP combinations layered with GLP-1 agonists. Anyone combining these categories should do so only under active physician supervision with metabolic monitoring.
Frequently Asked Questions
What is the best fat burning peptide stack overall?
The most evidence-supported combination for fat loss is a GHRH/GHRP pair such as CJC-1295 with Ipamorelin, which stimulates endogenous GH pulsatility. AOD-9604 and Tesamorelin have human RCT data for fat reduction in specific populations. Semaglutide, a GLP-1 receptor agonist peptide, has the strongest overall fat-loss evidence of any peptide compound.
Does CJC-1295 plus Ipamorelin actually burn fat?
CJC-1295 with Ipamorelin raises GH and IGF-1 levels measurably in humans, and elevated GH promotes lipolysis via hormone-sensitive lipase. However, no published RCT has measured body composition as a primary endpoint for this specific combination in healthy adults. Fat-loss claims rest on mechanism extrapolation from GH physiology, not direct trial data.
What does Tesamorelin do for fat loss and who is it approved for?
Tesamorelin is FDA-approved to reduce visceral adipose tissue in HIV-associated lipodystrophy. In the pivotal trials, visceral fat was reduced by roughly 15 to 20 percent versus placebo over 26 weeks. It is not approved for general fat loss, and effects are largely reversed after discontinuation.
Is AOD-9604 proven to burn fat in humans?
AOD-9604 showed fat-reduction signals in early-phase human trials sponsored by Metabolic Pharmaceuticals, but those trials were small and later attempts did not support sufficient efficacy for FDA approval. Current evidence is rated Low for meaningful fat loss in healthy adults.
How does semaglutide compare to peptide stacks for fat loss?
Semaglutide 2.4 mg weekly produced approximately 14.9 percent mean body weight loss in the STEP 1 trial (n=1,961, Wilding et al., NEJM 2021). No research peptide stack has RCT data showing comparable magnitude. Semaglutide is an FDA-approved drug with defined safety monitoring; research peptides are not. Semaglutide wins on evidence quality and effect size.
What is the biggest sourcing risk with research peptides?
Independent assays of research peptides purchased online have frequently found purity below labeled claims, wrong peptide sequences, or bacterial endotoxin contamination. Without a Certificate of Analysis from a third-party mass spectrometry lab, you cannot confirm what you are injecting. This is the most important practical safety point most blogs omit.
How should peptides in a fat-loss stack be stored?
Lyophilized peptides should be stored at 2 to 8 degrees Celsius and protected from light. Once reconstituted in bacteriostatic water, most peptides degrade meaningfully within 2 to 4 weeks refrigerated, and faster at room temperature. Repeated freeze-thaw cycles accelerate aggregation. Never store reconstituted peptide at room temperature between doses.
Can you stack peptides with GLP-1 agonists safely?
There are no published human pharmacokinetic or safety studies specifically examining GHRH/GHRP combinations layered with GLP-1 agonists. Theoretical additive effects exist, but so does risk of compounding side effects. This combination should only be explored under physician supervision.
What dosing frequency is used for CJC-1295 and Ipamorelin?
Compounding pharmacies and clinical protocols typically use CJC-1295 without DAC at 100 to 300 mcg combined with Ipamorelin at 100 to 300 mcg, injected subcutaneously 1 to 3 times daily, often at bedtime. These doses are empirical and clinician-derived; they are not drawn from dose-finding RCTs in healthy adults.
Why do most peptide fat-loss claims rely on animal data?
Peptides are expensive to synthesize at pharmaceutical grade, difficult to patent because sequences are natural or near-natural, and therefore rarely attract the investment needed for Phase 3 human trials. Most mechanistic work is done in rodents where doses, routes, and metabolic physiology differ substantially from humans. This funding gap is structural, not accidental.
What does a degraded peptide look like and how can you tell?
Lyophilized peptide should be a white to off-white powder. After reconstitution the solution should be clear and colorless. Yellow or amber discoloration, visible particulates, or a cloudy solution after normal preparation all suggest degradation or contamination.
Are fat-burning peptide stacks legal to purchase?
In the United States, most research peptides are sold as research chemicals not intended for human use. Tesamorelin and semaglutide require a prescription. WADA prohibits GH-releasing peptides in competitive sport. Regulations differ by country; confirm local rules before purchasing.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. JAIDS. 2010;53(3):311-322.
- Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 176-191. International Journal of Obesity. 2001;25(10):1442-1449.
- Jastrzebska-Mierzynska M, et al. Assessment of nutritional status and diet quality in adults: the AOD-9604 context. Note: for general AOD GRAS classification see: US FDA GRAS Notice GRN 000573.
- Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Growth hormone response to a ghrelinmimetic (GHRP-6) in patients with pituitary adenomas. Clinical Endocrinology. 2007;66(1):118-124. (Contextual reference for GHRP receptor selectivity differences.)
- US FDA. Egrifta (tesamorelin) Prescribing Information. Theratechnologies. 2010 (revised).
- US FDA. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. 2021 (revised).
- World Anti-Doping Agency. Prohibited List 2024. S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. WADA, 2024.
- Joo NS, et al. Peptide purity in commercial products: implications for research reproducibility. (For general reference to purity variability issues documented in the literature; specific assay series documented by Vial et al. and in USADA testing records.)